{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:03:59Z","timestamp":1792670639483,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.bmc.2025.118480","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T02:30:14Z","timestamp":1762482614000},"page":"118480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Pyranotacrines as prospective multi-target compounds against Alzheimer's disease"],"prefix":"10.1016","volume":"132","author":[{"given":"Salma","family":"Fares","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa M.","family":"El Husseiny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid B.","family":"Selim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.M.","family":"Massoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118480_bb0005","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/pr.54.3.469","article-title":"Amyloid precursor protein, presenilins, and \u03b1-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer\u2019s disease","volume":"54","author":"Suh","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0010","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1021\/jm0340602","article-title":"3-(4-{[Benzyl (methyl) amino] methyl} phenyl)-6, 7-dimethoxy-2 H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced \u03b2-amyloid aggregation: a dual function lead for Alzheimer\u2019s disease therapy","volume":"46","author":"Piazzi","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0015","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the \u03b2 secretase BACE1 for Alzheimer's disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bmc.2025.118480_bb0020","doi-asserted-by":"crossref","first-page":"26012","DOI":"10.1021\/acsomega.3c02051","article-title":"Modified tacrine derivatives as multitarget-directed ligands for the treatment of Alzheimer\u2019s disease: synthesis, biological evaluation, and molecular modeling study","volume":"29","author":"Fares","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.bmc.2025.118480_bb0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/S1474-4422(03)00502-7","article-title":"Treatment of Alzheimer's disease; current status and new perspectives","volume":"2","author":"Schelterns","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bmc.2025.118480_bb0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/01.jnen.0000228136.58062.bf","article-title":"Involvement of oxidative stress in Alzheimer disease","volume":"65","author":"Nunomura","year":"2006","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.bmc.2025.118480_bb0035","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10534-014-9728-5","article-title":"Homeostasis of metals in the progression of Alzheimer\u2019s disease","volume":"27","author":"Gonz\u00e1lez-Dom\u00ednguez","year":"2014","journal-title":"BioMetals"},{"key":"10.1016\/j.bmc.2025.118480_bb0040","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1152\/physrev.00023.2009","article-title":"Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process","volume":"90","author":"De Strooper","year":"2010","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0045","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4155\/fmc-2016-0003","article-title":"Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics","volume":"8","author":"Rosini","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0050","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0055","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1093\/brain\/awl280","article-title":"Therapeutic approaches to Alzheimer\u2019s disease","volume":"129","author":"Klafki","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.bmc.2025.118480_bb0060","first-page":"34","article-title":"The cholinergic hypothesis: a historical overview, current perspective, and future directions","volume":"5","author":"Bartus","year":"1985","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.bmc.2025.118480_bb0065","article-title":"Aducanumab: a new hope in Alzheimer\u2019s disease","volume":"4","author":"Ali","year":"2022","journal-title":"Health Sci, Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0070","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejmech.2018.01.055","article-title":"Design, synthesis and biological evaluation of new coumarin-dithiocarbamate hybrids as multifunctional agents for the treatment of Alzheimer's disease","volume":"146","author":"Jiang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0075","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0006-2952(02)01514-9","article-title":"\u03b2-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies","volume":"65","author":"Bartolini","year":"2003","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bmc.2025.118480_bb0080","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1021\/jm401824w","article-title":"Synthesis and multitarget biological profiling of a novel family of rhein derivatives as disease-modifying anti-Alzheimer agents","volume":"57","author":"Viayna","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0085","doi-asserted-by":"crossref","first-page":"17213","DOI":"10.1073\/pnas.0508575102","article-title":"Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer \u03b2-amyloid peptide in rodent","volume":"102","author":"Greig","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bmc.2025.118480_bb0090","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2019.02.001","article-title":"Synthesis and evaluation of novel GSK-3\u03b2 inhibitors as multifunctional agents against Alzheimer\u2019s disease","volume":"167","author":"Shi","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0095","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.bmc.2015.02.041","article-title":"\u03b2-sheet interfering molecules acting against \u03b2-amyloid aggregation and fibrillogenesis","volume":"23","author":"Francioso","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0100","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.2174\/092986710791959729","article-title":"Beta amyloid aggregation inhibitors: small molecules as candidate drugs for therapy of Alzheimer's disease","volume":"17","author":"Re","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0105","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0896-6273(00)80115-4","article-title":"Mechanisms of neuronal degeneration in Alzheimer\u2019s disease","volume":"16","author":"Yankner","year":"1996","journal-title":"Neuron"},{"key":"10.1016\/j.bmc.2025.118480_bb0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tips.2009.05.002","article-title":"Alzheimer\u2019s disease, metal ions and metal homeostatic therapy","volume":"30","author":"Zatta","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.bmc.2025.118480_bb0115","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1021\/bi7000032","article-title":"Metal ions differentially influence the aggregation and deposition of Alzheimer\u2019s \u03b2-amyloid on a solid template","volume":"46","author":"Ha","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2025.118480_bb0120","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.drudis.2020.12.004","article-title":"Role of reactive oxygen species in the progression of Alzheimer\u2019s disease","volume":"26","author":"Bhatt","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bmc.2025.118480_bb0125","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0197-4580(95)00066-N","article-title":"Are reactive oxygen species involved in Alzheimer's disease","volume":"16","author":"Benzi","year":"1995","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.bmc.2025.118480_bb0130","doi-asserted-by":"crossref","first-page":"39695","DOI":"10.1074\/jbc.M102334200","article-title":"Calcium entry through L-type calcium channels causes mitochondrial disruption and chromaffin cell death","volume":"276","author":"Cano-Abad","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0135","series-title":"Calcium Dysregulation in Alzheimer's Disease","first-page":"1275","volume":"14","author":"Bojarski","year":"2011"},{"key":"10.1016\/j.bmc.2025.118480_bb0140","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1017\/S1461145711000149","article-title":"Increased NF-\u03baB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer\u2019s disease","volume":"15","author":"Chen","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.bmc.2025.118480_bb0145","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1089\/ars.2010.3359","article-title":"Calcium dysregulation and homeostasis of neural calcium in the molecular mechanisms of neurodegenerative diseases provide multiple targets for neuroprotection","volume":"14","author":"Zundorf","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.bmc.2025.118480_bb0150","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bph.12240","article-title":"Calcium channel blockers and dementia","volume":"169","author":"Nimmrich","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bmc.2025.118480_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuint.2016.07.003","article-title":"Nimodipine, an L-type calcium channel blocker attenuates mitochondrial dysfunctions to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice","volume":"99","author":"Singh","year":"2016","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.bmc.2025.118480_bb0160","first-page":"27","article-title":"Nifedipine: can this calcium channel blocker be used \u201coff label\u201d to inhibit the development and symptoms of Alzheimer\u2019s disease and related Beta-amyloid-producing syndromes","volume":"5","author":"Jomsky","year":"2019","journal-title":"Toxicol"},{"key":"10.1016\/j.bmc.2025.118480_bb0165","series-title":"Diagnosis and Treatment of Senile Dementia","first-page":"366","article-title":"Nimodipine in the treatment of Alzheimer\u2019s disease","volume":"7","author":"Baumel","year":"1989"},{"key":"10.1016\/j.bmc.2025.118480_bb0170","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.1021\/jm00095a023","article-title":"Dihydropyrimidine calcium channel blockers: basic 3-substituted-4-aryl-1,4-dihydropyrimidine-5-carboxylic acid esters are potent antihypertensive agents","volume":"35","author":"Rovnyak","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0175","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1248\/cpb.33.3787","article-title":"New 1, 4-dihydropyridine derivatives with potent and long-lasting hypotensive effect","volume":"33","author":"Meguro","year":"1985","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.bmc.2025.118480_bb0180","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.1016\/j.tetlet.2012.10.020","article-title":"A facile one-pot synthesis of 2-thioxo-dihydropyrimidines and polyfunctionalized pyran derivatives as mimics of novel calcium channel modulators","volume":"53","author":"Yadlapalli","year":"2012","journal-title":"Tetrahedron Lett."},{"key":"10.1016\/j.bmc.2025.118480_bb0185","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/S0960-894X(03)00560-2","article-title":"4-phenyl-4H-pyrans as IKCa channel blockers","volume":"13","author":"Urbahns","year":"2003","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2025.118480_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pneurobio.2015.12.003","article-title":"Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease","volume":"151","author":"Ismaili","year":"2017","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bmc.2025.118480_bb0195","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejmech.2016.10.060","article-title":"A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease","volume":"128","author":"Sameem","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0200","first-page":"3000","article-title":"Therapeutic agents in Alzheimer\u2019s disease through a multi-targetdirected ligands strategy: recent progress based on tacrine core","volume":"17","author":"Dorababu","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"24","key":"10.1016\/j.bmc.2025.118480_bb0205","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1016\/S0960-894X(97)10165-2","article-title":"Friedlander reaction on 2-amino-3-cyano-4H-pyrans: synthesis of derivatives of 4H-pyran[2,3-b]quinoline, new tacrine analogs","volume":"7","author":"Martinez-Grau","year":"1997","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bmc.2025.118480_bb0210","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1016\/j.bmcl.2013.02.017","article-title":"Novel tacrine-related drugs as potential candidates for the treatment of Alzheimer\u2019s disease","volume":"23","author":"Romero","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.bmc.2025.118480_bb0215","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0968-0896(01)00378-9","article-title":"Novel tacrine derivatives that block neuronal calcium channels","volume":"10","author":"de los Rios","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0220","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejmech.2016.04.023","article-title":"Potent anticholinesterasic and neuroprotective pyranotacrines as inhibitors of beta-amyloid aggregation, oxidative stress and tau-phosphorylation for Alzheimer's disease","volume":"118","author":"Garcia-Font","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0225","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3390\/molecules21040400","article-title":"Imidazopyranotacrines as non-hepatotoxic, selective acetylcholinesterase inhibitors, and antioxidant agents for Alzheimer\u2019 s disease therapy","volume":"21","author":"Boulebd","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.bmc.2025.118480_bb0230","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.2174\/1568026618666180112155639","article-title":"Recent developments on multi-target-directed tacrines for Alzheimer's disease. I. The pyranotacrines","volume":"17","author":"Romero","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0235","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ejmech.2017.01.042","article-title":"New tacrine-derived AChE\/BuChE inhibitors: synthesis and biological evaluation of 5-amino-2-phenyl-4H-pyrano[2,3-b]quinoline-3-carboxylates","volume":"128","author":"Eghtedari","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0240","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ejmech.2006.06.016","article-title":"Synthesis and biological evaluation of new 4H-pyrano[2,3-b]quinoline derivatives that block acetylcholinesterase and cell calcium signals, and cause neuroprotection against calcium overload and free radicals","volume":"41","author":"Marco-Contelles","year":"2006","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0245","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ejmech.2017.08.013","article-title":"Novel tacrine derivatives exhibiting improved acetylcholinesterase inhibition: design, synthesis and biological evaluation","volume":"139","author":"Reddy","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0250","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1016\/j.bmc.2013.04.054","article-title":"Antagonism of L-type Ca2+ channels CaV1.3 and CaV1.2 by 1,4-dihydropyrimidines and 4H-pyrans as dihydropyridine mimics","volume":"21","author":"Kang","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0255","doi-asserted-by":"crossref","first-page":"8176","DOI":"10.1016\/j.bmc.2006.09.025","article-title":"New multipotent tetracyclic tacrines with neuroprotective activity","volume":"14","author":"Marco-Contelles","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0260","doi-asserted-by":"crossref","DOI":"10.1021\/cr800482c","article-title":"Recent advances in the Friedla\u00a8nder reaction","volume":"109","author":"Marco-Contelles","year":"2009","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103076","article-title":"Dihydrofolate reductase inhibition effect of 5-substituted pyrido[2,3-d]pyrimidines: synthesis, antitumor activity and molecular modeling study","volume":"90","author":"Abdelaziz","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0270","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bmc.2025.118480_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105216","article-title":"Biphenylpiperazine based MAO inhibitors: synthesis, biological evaluation, reversibility and molecular modeling studies","volume":"115","author":"El-Halaby","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104792","article-title":"Design and synthesis of novel coumarin derivatives as potential acetylcholinesterase inhibitors for Alzheimer\u2019s disease","volume":"110","author":"Amin","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0285","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.bmc.2015.03.051","article-title":"Synthesis of new N-benzylpiperidine derivatives as cholinesterase inhibitors with \u03b2-amyloid anti-aggregation properties and beneficial effects on memory in vivo","volume":"23","author":"Wi\u0119ckowska","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0290","doi-asserted-by":"crossref","DOI":"10.1098\/rsos.160696","article-title":"Thioflavin T as an amyloid dye: fibril quantification, optimal concentration and effect on aggregation","volume":"4","author":"Xue","year":"2017","journal-title":"R. Soc. Open Sci."},{"key":"10.1016\/j.bmc.2025.118480_bb0295","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jnr.20025","article-title":"Curcumin has potent anti-amyloidogenic effects for Alzheimer's \u03b2-amyloid fibrils in vitro","volume":"75","author":"Ono","year":"2004","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.bmc.2025.118480_bb0300","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1016\/j.bmc.2018.04.043","article-title":"Novel 8-hydroxyquinoline derivatives targeting beta-amyloid aggregation, metal chelation and oxidative stress against Alzheimer's disease","volume":"26","author":"Yang","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0305","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1021\/jf9505685","article-title":"Antioxidant activity of \u03b1-tocopherol and trolox in different lipid substrates: bulk oils vs oil-in-water emulsions","volume":"44","author":"Huang","year":"1996","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0310","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2174\/1570159X11311030006","article-title":"Acetylcholinesterase inhibitors: pharmacology and toxicology","volume":"11","author":"Colovic","year":"2013","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.bmc.2025.118480_bb0315","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.tiv.2014.11.009","article-title":"Liposomes and MTT cell viability assay: an incompatible affair","volume":"29","author":"Angius","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.bmc.2025.118480_bb0320","doi-asserted-by":"crossref","first-page":"5193","DOI":"10.1021\/cr300009x","article-title":"Bioinorganic chemistry of Alzheimer\u2019s disease","volume":"112","author":"Kepp","year":"2012","journal-title":"Chem. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0325","doi-asserted-by":"crossref","first-page":"6672","DOI":"10.1039\/C4CS00005F","article-title":"Cholesterol and metal ions in Alzheimer\u2019s disease","volume":"43","author":"Lee","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0330","doi-asserted-by":"crossref","unstructured":"Blood\u2212Brain Barrier (BBB) Prediction Server, 2023. http:\/\/ www.cbligand.org\/BBB\/index.php. doi:https:\/\/doi.org\/10.1039\/c4cs00005f.","DOI":"10.1039\/C4CS00005F"},{"key":"10.1016\/j.bmc.2025.118480_bb0335","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.addr.2012.09.019","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"64","author":"Lipinski","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0340","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bmc.2025.118480_bb0345","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0350","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0360","doi-asserted-by":"crossref","first-page":"4066","DOI":"10.1021\/acs.jmedchem.5b00104","article-title":"pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures","volume":"58","author":"Pires","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bmc.2025.118480_bb0365","first-page":"215","article-title":"Cholinesterase inhibitors for Alzheimer\u2019s disease","volume":"4","author":"Birks","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bmc.2025.118480_bb0370","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6","article-title":"Automated docking of flexible ligands: applications of AutoDock","volume":"9","author":"Goodsell","year":"1996","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.bmc.2025.118480_bb0375","series-title":"Using AutoDock 4 and AutoDock vina with AutoDockTools: A tutorial","first-page":"92037","volume":"10550","author":"Huey","year":"2012"},{"key":"10.1016\/j.bmc.2025.118480_bb0380","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/138161206775193127","article-title":"The peripheral anionic site of acetylcholinesterase: structure, functions and potential role in rational drug design","volume":"12","author":"Johnson","year":"2006","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bmc.2025.118480_bb0385","first-page":"54","article-title":"Butyrylcholinesterase: structure and physiological importance","volume":"28","author":"\u00c7oku\u011fra\u015f","year":"2003","journal-title":"Turk. J. Biochem."},{"key":"10.1016\/j.bmc.2025.118480_bb0390","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1042\/BJ20130013","article-title":"Crystal structures of human cholinesterases in complex with huprine W and tacrine: elements of specificity for anti-Alzheimer's drugs targeting acetyl- and butyryl-cholinesterase","volume":"453","author":"Nachon","year":"2013","journal-title":"Biochem. J."},{"key":"10.1016\/j.bmc.2025.118480_bb0395","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.2174\/13816128113199990068","article-title":"Inhibition of amyloid-\u03b2 aggregation in Alzheimer's disease","volume":"20","author":"Wang","year":"2014","journal-title":"Curr. Pharmacol. Dis."},{"key":"10.1016\/j.bmc.2025.118480_bb0400","doi-asserted-by":"crossref","first-page":"6003","DOI":"10.1021\/bi0474867","article-title":"A\u03b240-lactam(D23\/K28) models a conformation highly favorable for nucleation of amyloid","volume":"44","author":"Sciarretta","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.bmc.2025.118480_bb0405","doi-asserted-by":"crossref","DOI":"10.1002\/ardp.201700403","article-title":"Design, synthesis, and molecular modeling of heterocyclic bioisostere as potent PDE4 inhibitors","volume":"351","author":"Almatary","year":"2018","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bmc.2025.118480_bb0410","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0006-2952(61)90145-9","article-title":"A new and rapid colorimetric determination of acetylcholinesterase activity","volume":"7","author":"Ellman","year":"1961","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bmc.2025.118480_bb0415","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1002\/cbic.200700427","article-title":"Insight into the kinetic of amyloid \u03b2(1\u201342) peptide self-aggregation: elucidation of inhibitors mechanism of action","volume":"8","author":"Bartolini","year":"2007","journal-title":"Chembiochem"},{"key":"10.1016\/j.bmc.2025.118480_bb0420","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejmech.2019.04.038","article-title":"A multifunctional therapeutic approach: synthesis, biological evaluation, crystal structure and molecular docking of diversified 1H-pyrazolo[3,4-b]pyridine derivatives against Alzheimer\u2019s disease","volume":"175","author":"Umar","year":"2019","journal-title":"Eur. J. Med. Chem."}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625004213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:04:04Z","timestamp":1780635844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625004213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":83,"alternative-id":["S0968089625004213"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118480","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pyranotacrines as prospective multi-target compounds against Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118480"}}